Mounjaro®
Starting from £179.99/mo
Start journey Learn moreUK clinical guidance is clear: Wegovy (semaglutide) is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. If you are planning a pregnancy, you should stop Wegovy before you start trying, and allow a wash-out period beforehand — your prescriber or GP will advise on the timing based on your individual circumstances. What that period looks like, and how to manage your weight in the interim, is worth thinking through carefully before you reach that point. These are prescription medicines that require clinical assessment; decisions about stopping or continuing treatment always rest with your prescribing clinician, not a general guide. If you have questions about your specific situation, speak to our prescribers or your GP.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The starting point here is pharmacological, not precautionary folklore. Semaglutide has a half-life of roughly one week, meaning it takes several weeks to clear the body after the final dose. The NHS semaglutide medicines page states directly that Wegovy should not be used in pregnancy or while breastfeeding, and that women who could become pregnant should use effective contraception during treatment. The MHRA, in its public guidance on GLP-1 medicines, reinforces that these treatments should be stopped before trying to conceive, with a wash-out period observed.
There is a misconception worth addressing gently: some people assume that because Wegovy supports better metabolic health, continuing it through early pregnancy might actually help. Current evidence does not support this. Animal studies have shown developmental effects at high doses, and there is no adequate human safety data for use in pregnancy. That is why the guidance exists, and it is consistent across the Summary of Product Characteristics, NHS clinical pages, and specialist weight-management guidance.
The practical upshot: if you are thinking about pregnancy in the next several months, now is the time to raise it with your prescriber, not the week you decide to start trying. Planning gives you and your clinical team room to taper or stop treatment in a structured way rather than an abrupt one.
This is the question our prescribers hear regularly, and the honest answer is that published guidance does not specify a single universal figure. The NHS England weight-management injections guidance advises using contraception during treatment and discusses stopping before conception, while deferring the precise wash-out period to the prescriber's assessment of the individual patient.
What is known is that semaglutide's pharmacokinetics mean it takes approximately five half-lives (roughly five weeks) for plasma levels to fall to negligible amounts after the last injection. Many clinicians use this as a minimum baseline for discussion, but individual factors including your dose, how long you have been on treatment, and any other medicines or conditions you have will all influence the guidance you receive. This is not a decision to navigate from a forum thread.
If you have been on Wegovy for some time and are approaching the stage where you want to conceive, a conversation with your GP or a specialist prescriber is the right first step. You can read more about the broader evidence picture on our semaglutide and pregnancy page.
For many people, weight management after stopping any GLP-1 medicine is a genuine concern. The STEP 1 trial, published in the New England Journal of Medicine, found that participants who discontinued semaglutide regained a substantial proportion of lost weight over the following year without continued treatment and lifestyle support. That context matters when planning a pre-conception pause.
The good news is that the period between stopping Wegovy and conceiving is not a vacuum. It is an opportunity to consolidate habits, focus on nutrition that will also serve a healthy pregnancy, and work with your clinical team on a structured plan. Protein adequacy, hydration, and sustainable activity all continue to matter; your prescriber or a registered dietitian can help you translate what worked on treatment into something maintainable off it.
Wegovy's weight-management licence and the evidence supporting it are covered in detail on our Wegovy overview page. For a broader look at the treatment options available to you, including what to consider when you are ready to return to treatment after pregnancy, the returning to Wegovy after pregnancy page walks through the considerations.
If you discover an unplanned pregnancy while taking Wegovy, stop the medicine and contact your GP or midwife the same day. Do not wait for a scheduled review. This is not a situation that calls for alarm, but it does require prompt clinical input so that your pregnancy care can be properly set up and any necessary monitoring arranged.
For planned pregnancies, your GP is the right starting point for coordinating pre-conception care, including when to stop Wegovy and what, if anything, to do in the interim period. If your weight management has been overseen by a specialist service, loop them in too. Our own prescribers are available if you have questions about the Wegovy side of the picture, you can reach our team seven days a week, or read more about how our clinical oversight works on the clinical team page.
Related questions we cover elsewhere: the evidence on how Wegovy may affect pregnancy, what is known about Wegovy and pregnancy more broadly, and considerations around stopping Wegovy before surgery, a situation that shares some of the same planning logic.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.